Royalty Report: Drugs, Cancer, Autoimmune – Collection: 269086


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Cancer
  • Autoimmune
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Drug Discovery
  • Kidneys
  • cardiac
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 269086

License Grant
This exclusive license agreement with Licensee is to commercialize fostamatinib in all indications, including chronic ITP, AIHA, and IgAN, in Europe and Turkey.  Licensee will receive exclusive rights to fostamatinib in human diseases, including chronic immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN).
License Property
Fostamatinib refers to fostamatinib disodium hexahydrate which is an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment (product called TAVALISSE®)

The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Field of Use
Fostamatinib is a medication for the treatment of chronic immune thrombocytopenia.

Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.

IPSCIO Record ID: 337709

License Grant
The parties agree to commercialize fostamatinib in all potential indications, including chronic ITP and AIHA, in Canada and Israel.
License Property
Fostamatinib has the brand name of Tavlesse (Tavalisse). It is a tablet, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.

ITP means immune thrombocytopenia where the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.

Field of Use
Field of use is for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments and to reduce the destruction of red blood cells in the AIHA disease.

AIHA means autoimmune hemolytic anemia.  It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.

IPSCIO Record ID: 6490

License Grant
The U.S. Food and Drug Administration, granted approval of Promacta for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta is the first oral thrombopoietin, or TPO, receptor agonist therapy for the treatment of adult patients with chronic ITP.  Thrombocytopenia is any disorder in which there are not enough platelets. Platelets are cells in the blood that help blood to clot. This condition is sometimes associated with abnormal bleeding. As stated in the License agreement the Licensor will receive royalties from the Licensee based on the FDA approval.

In addition to the approval granted for GSK’s Promacta for the treatment of thrombocytopenia in patients with chronic ITP, the compound is also being studied for thrombocytopenia associated with chronic hepatitis C virus, chronic liver disease and oncology-related thrombocytopenia. Two Phase III studies in hepatitis C and one Phase III in chronic liver disease are ongoing. In December 2008, GSK submitted a marketing authorization application in the EU and international for Revolade (Eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP.

Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 304790

License Grant
Licensee of Sweden was granted (i) an exclusive license to certain patents and joint intellectual property developed with Licensor and (ii) a non-exclusive license to certain of Licensor know-how as necessary or useful to develop and commercialize Nefecon or other product candidates.
License Property
Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant. Nefecon is currently the only pharmaceutical candidate in development for IgAN that is intended to be disease-modifying. Nefecon targets the ileum, the distal region of the small intestine, which is the presumed origin of IgAN due to the ileum being the location of the highest concentration of the Peyer’s patches, which are responsible for the production of secretory immunoglobulin A, or IgA, antibodies. Nefecon has been granted orphan drug designation for the treatment of IgAN in the United States and the European Union.
Field of Use
The filed of use is for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN for which there is a high unmet medical need and there are no approved treatments. IgAN is a progressive, chronic disease that over time results in deterioration of kidney function in patients, many of whom end up at risk of developing end-stage renal disease, or ESRD, with the need for dialysis or kidney transplant.

IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.

Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.  Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.

IPSCIO Record ID: 336329

License Grant
Licensor hereby grants to Licensee an exclusive (even as to Licensor) royalty-bearing, worldwide, perpetual, irrevocable right and license under the Licensed Patents and Licensed Know-How in the Territory to Develop, Commercialize, make, have made, use, have used, import, sell, offer for sale and have sold Licensed Compounds and Licensed Products in any and all fields in the Territory. Such license shall further include the right to grant sublicenses to Affiliates of Licensee and to Third Parties in accordance with the terms set forth. For the avoidance of doubt, Licensor shall retain rights under the Licensed Patents and Licensed Know-How to use LGD-4665 and other Licensed Compounds for its internal or partnered research and development purposes.
License Property
Promacta® / Revolade® is an oral thrombopoietin receptor agonist (TPO-RA).

LGD-4665 is a matter of oral thrombopoietin mimetic.

U. S. Patent #7314887 – Thrombopoietin activity modulating compounds and methods

Licensed Compound means any and all thrombopoietin mimetics Controlled by Licensor or its Affiliate during the Term of the Agreement including (a) that certain compound known as LGD-4665 with the molecular structure shown in this Agreement, and all formulations including intravenous formulations), salts, prodrugs, hydrates, solvates, polymorphs, enantiomers and isomers thereof; (b) any back-up compounds to LGD-4665 being developed by Licensor as of the Execution Date, as shown on, or incorporated by reference; and (c) any other thrombopoietin mimetic compounds that are Covered by the Licensed Patents. Notwithstanding the foregoing, for the purpose of this Agreement, an Affiliate shall not include any Third Party which acquires control over Licensor or over which Licensor acquires control after the Execution Date so long as such Third Party does not otherwise become involved in the conduct of Development or Commercialization of the Licensed Compounds.

Field of Use
Field of use is for the treatment of thrombocytopenia in pediatric patients 1 year and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.  A Bone marrow stimulant that can treat thrombocytopenia and aplastic anemia.

Thrombopoietin (THPO) also known as megakaryocyte growth and development factor (MGDF) is a protein that in humans is encoded by the THPO gene. Thrombopoietin is a glycoprotein hormone produced by the liver and kidney which regulates the production of platelets.

Severe aplastic anemia is a rare, life-threatening, acquired blood disorder in which a patients bone marrow fails to produce enough red blood cells, white blood cells, and platelets[5].

IPSCIO Record ID: 365047

License Grant
The parties partnered in a Study of Sparsentan where the Licensor is entitled to compensation upon NDA submission.
License Property
Sparsentan, an investigational product candidate for the treatment of IgA nephropathy (“IgAN”). The Protect Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than threefold reduction of proteinuria from baseline after 36 weeks of treatment,
Field of Use
Field of use is for the treatment of IgA nephropathy (“IgAN”).

IgA nephropathy, a rare, immune complex mediated chronic glomerular disease.

Glomerular diseases affect the filtering units of your kidney, the glomeruli. Symptoms include foamy urine, pink urine, high blood pressure and swelling in your face, hands, ankles or feet. Many diseases can cause glomerular disease. The leading cause is diabetic nephropathy.

IPSCIO Record ID: 204382

License Grant
The Licensor and the Licensee wish to resolve the dispute regarding Licensees Commercially Reasonable Efforts to Develop the controlled release formulation of anagrelide by making certain amendments to the License Agreement.  Anagrelide is a treatment for thrombocythemia – the overproduction of blood platelets.
License Property
Essential thrombocythemia (ET) is a rare chronic blood condition characterised by the overproduction of platelets by megakaryocytes in the bone marrow.  Essential thrombocythemia (ET) is one of a related group of blood cancers known as “myeloproliferative neoplasms” (MPNs) in which cells in the bone marrow that produce the blood cells develop and function abnormally. … ET does not generally shorten life expectancy.

The Licensor is a biotechnology company, developing and commercializing drugs and devices for the control of hyperplasia associated with vascular procedures and control of cardiovascular risk factors.

Field of Use
The Licensee designs and develops active ingredient anagrelide, GALE-401 (Anagrelide CR) used for treatment of Essential Thrombocythemia.

IPSCIO Record ID: 694

License Grant
The Licensor desires to exclusively License to the Licensee all of the Licensor's rights in and to LGD-4665, the oral thrombopoietin mimetic, its back-ups, and all related compounds covered by patent rights. This worldwide License shall be irrevocable and sublicensable until patent expiration or ten years from the first commercial sale.
License Property
Licensed Compound means any and all thrombopoietin mimetics.

Licensed Product means any pharmaceutical preparation in any formulation or form containing one or more Licensed Compounds as its active ingredients for use in any field.

LGD-4665 increases platelet counts in a dose proportional manner, and is associated with a high safety margin in healthy subjects after single and multiple daily, or weekly doses.  LGD-4665 has shown a promising profile of thrombopoietin receptor agonist activity in Phase I studies, and in terms of efficacy, potency and selectivity has the potential to become a competitive molecule for the treatment of different forms of thrombocytopenia. Thrombocytopenia or low platelet count is a common clinical finding associated with a diverse group of clinical disorders or conditions affecting platelet production and/or survival. Prevalent clinical disorders where platelet loss or dysfunction leads to significant morbidity include hepatitis C, chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), idiopathic thrombocytopenic purpura (ITP) and several other cancers and liver diseases.

Field of Use
The rights granted apply to pharmaceutical preparation with active ingredients for use in any field.

IPSCIO Record ID: 183244

License Grant
Licensor granted an exclusive, worldwide license to develop and commercialize cerdulatinib in topical formulation for all indications, excluding oncology to German Licensee.
License Property
Cerdulatinib, is an orally available dual kinase inhibitor that inhibits spleen tyrosine kinase, or Syk, and Janus kinases, or JAK, enzymes that regulate important signaling pathways.  Cerdulatinib is being developed for hematologic, or blood, cancers and inflammatory disorders.
Field of Use
Licensee intends to develop it for the topical treatment of a range of dermatologic conditions.

This agreement is for the pharmaceutical industry, excluding oncology use.

IPSCIO Record ID: 359530

License Grant
Licensee acquires IMU-838 and IMU-935 from German Licensor.
License Property
IMU-838, targets DHODH, a key enzyme in the intracellular metabolism of immune cells in the body. The IMU-838 program is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (“DHODH”).

IMU-935, is a highly potent and selective inverse agonist of a transcription factor called ROR?t with additional activity on DHODH. IMU-935 program is focused on an inverse agonist of ROR?t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (“ROR?”).

Field of Use
Field of use is for selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis (“RRMS”), ulcerative colitis (“UC”), Crohn’s disease (“CD”) and psoriasis.

IPSCIO Record ID: 336293

License Grant
Licensor hereby grants to Licensee an exclusive, worldwide, royalty-bearing license under the Licensor Technology to make, have made, import, use, offer for sale and sell the Product for use in the Field in the Territory. The preceding rights granted Licensee to make and have made the Product shall only become effective upon receipt by Licensor of notice from Licensee that Licensee wishes to manufacture the Product.
License Property
Product shall mean a monoclonal antibody which is within the scope of U.S. Patent No. 4,954,617, and which has an antigen binding region having a binding affinity for cd64. As used herein, cd64 shall mean the human high affinity Fc receptor for IgG present on macrophages and monocytes. For the avoidance of doubt, it is understood that any other monoclonal antibody, including without limitation, a bifunctional antibody or a hetero antibody or a single chain antibody, shall not be a Product. The humanized anti-cd64 monoclonal antibody known as H-22 shall be the Product for initial development under the Development Program.

4,954,617 – Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes

Field of Use
Field shall mean treatment of human hematologic auto/allo-immune diseases in which antibodies-coated blood cellular components are destroyed through the RES by phagocytosis, including but not limited to the following
ITP, drug induced
Auto-immune Hemolytic Anemia (AIHA)
Auto-immune Neutropenia
Allo-immune Thrombocytopenia.
Pure Red Cell Aplasia
Hemolytic Disease of the Newbom (HDN)
Hematophagocytic Syndrome
Purpura, post transfusion
Thrombocytopenia, neonatal allo-immune

ITP means idiopathic thrombocytopenia purpura.

IPSCIO Record ID: 123666

License Grant
Licensee exercised the right to enter into an exclusive license agreement.  In December 2015, the parties entered into an option agreement to explore a novel approach to develop a drug in the field of hypercholesterolemia.
License Property
The developed drug would be a spleen tyrosine kinase or Syk inhibitors,  a drug in the field of hypercholesterolemia.
Hypercholesterolemia, also called dyslipidemia, is the presence of high levels of cholesterol in the blood.
Field of Use
Licensee is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic diseases and inflammation for patients who currently have limited or no approved treatment options.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.